A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults

Abstract

BackgroundInvasive pneumococcal disease (IPD) and pneumococcal pneumonia are common and carry a significant morbidity and mortality. Current strategies to prevent pneumococcal disease are under review in the United Kingdom (UK). We conducted a systematic review to evaluate the burden of vaccine type adult pneumococcal disease specifically in the UK.MethodsA systematic review conducted and reported according to MOOSE guidelines. Relevant studies from 1990 to 2015 were included. The primary outcome was the incidence of vaccine type pneumococcal disease, focussing on the pneumococcal polysaccharide vaccine (PPSV), the 13-valent conjugate vaccine (PCV13) and the 7-valent conjugate vaccine (PCV7).ResultsData from surveillance in England and Wales from 2013/14 shows an incidence of 6.85 per 100,000 population across all adult age groups for IPD, and an incidence of 20.58 per 100,000 population in those aged >65 years. The corresponding incidences for PCV13 serotype IPD were 1.4 per 100,000 and 3.72 per 100,000. The most recent available data for community-acquired pneumonia (CAP) including non-invasive disease showed an incidence of 20.6 per 100,000 for adult pneumococcal CAP and 8.6 per 100,000 population for PCV13 serotype CAP. Both IPD and CAP data sources in the UK suggest an ongoing herd protection effect from childhood PCV13 vaccination causing a reduction in the proportion of cases caused by PCV13 serotypes in adults. Despite this, applying the incidence rates to UK population estimates suggests more than 4000 patients annually will be hospitalised with PCV13 serotype CAP and more than 900 will be affected by IPD, although with a trend for these numbers to decrease over time.There was limited recent data on serotype distribution in high risk groups such as those with chronic respiratory or cardiac disease and no data available for vaccine type (VT) CAP managed in the community where there is likely to be a considerable unmeasured burden.ConclusionThe most recent available data suggests that VT pneumococcal disease continues to have a high burden in UK adults despite the impact of childhood PCV13 vaccination. IPD estimates represent only a fraction of the total burden of pneumococcal disease.Study registrationPROSPERO CRD42015025043Electronic supplementary materialThe online version of this article (doi:10.1186/s12890-016-0242-0) contains supplementary material, which is available to authorized users.

Composition and immunological significance of the upper respiratory tract microbiota

“…Immunosenenescence, which is defined as age‐related changes in immune function, is a major contributing factor to the increased incidence of respiratory infections in people over 65 years old . It is unclear how immunosenescence affects the composition and maintenance of the URT microbiota, although there are associations with the immune status and dysbiosis of the intestinal microbiota .…”

Pneumococcal Capsular Polysaccharide Immunity in the Elderly

“…However, serotype replacement has abrogated much of this benefit in many settings (64,65). Even without significant levels of serotype replacement, vaccine-type disease remains common in older people after childhood vaccination programs are established (66), and residual non-vaccine-type disease will persist as a public health problem (5).…”

Vacunación neumocócica conjugada en adultos. Recomendaciones de las Sociedades Médicas en México

“…Sin embargo, la manifestación más frecuente de la enfermedad neumocócica, es la neumonía neumocócica per se, donde el neumococo puede ser responsable de hasta 60% de los casos de NAC. 4 Si bien, de manera fisiológica, las barreras mecánicas proporcionan la defensa inicial del tracto respiratorio filtrando los microorganismos de la corriente de aire a través de las vibrisas nasales, y las vías aéreas de ramificación sirven para evitar que los patógenos entren en el tracto respiratorio inferior (células epiteliales ciliadas y secreciones de las vías respiratorias). Cuando es rebasada la capacidad de los macrófagos alveolares para fagocitar los microorganismos, se traduce en neumonía clínica, desencadenándose una respuesta inflamatoria mediada por los macrófagos para reforzar las defensas, siendo este factor el que desencadena el síndrome clínico de neumonía.…”